A physician-initiated double-blind, randomised, placebo-controlled , phase 2 study evaluating the efficacy and safety of inhibition of NADPH Oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion.

Trial Profile

A physician-initiated double-blind, randomised, placebo-controlled , phase 2 study evaluating the efficacy and safety of inhibition of NADPH Oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion.

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Oct 2017

At a glance

  • Drugs GKT 831 (Primary)
  • Indications Diabetic nephropathies
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Oct 2017 According to a GenKyoTex media release, the company is on track to enroll the first patient by the end of 2017.
    • 21 Jul 2017 New trial record
    • 28 Jun 2017 According to a GenKyoTex media release, Professor Mark Cooper (Head of the Department of Diabetes at Monash University) and Professor Jonathan Shaw (Deputy Director, at the Baker Heart and Diabetes Institute in Melbourne) will lead the conduct of trial. This study will be based at the Baker institute and is financially supported by JDRF Australia.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top